Acurx Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Acurx Pharmaceuticals, Inc. (ACXP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 0.30% for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-15.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2024-03-15
- Acurx Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 0.30%, a 70.00% decline from fiscal 2021.
- Acurx Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was 1.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2022-12-31 | 0.30% 10-K · filed 2024-03-15 |
| 2021-12-31 | 1.00% 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |